Health Care [ 12/12 ] | Pharmaceuticals [ 64/74 ]
NASDAQ | Common Stock
Pulmatrix, Inc., a clinical stage biotechnology company, focused on development of novel inhaled therapeutic products to prevent and treat respiratory and other diseases with unmet medical needs in the United States.
The company offers iSPERSE, an engineered dry powder delivery platform, which enables delivery of small or large molecule drugs to the lungs by inhalation for local or systemic applications.
It engages in developing PUR1800, a narrow spectrum kinase inhibitor completed Phase 1b clinical trials for the treatment of acute exacerbations in chronic obstructive pulmonary disease; PUR1900 for the treatment of allergic bronchopulmonary aspergillosis in patients with asthma and cystic fibrosis; and PUR3100, an iSPERSE formulation of dihydroergotamine which is in Phase 1 for the treatment of acute migraine.
It has a license agreement with RespiVert Ltd. for access to a portfolio of kinase inhibitor drug candidates.
The company was founded in 2003 and is headquartered in Bedford, Massachusetts.
| Reported date | EPSChange YoY | EstimateSurprise |
|---|---|---|
| Aug 13, 24 | -1.59 Decreased by -52.99% | - |
| May 10, 24 | 0.23 Increased by +118.52% | - |
| Mar 28, 24 | -0.57 Increased by +50.00% | -1.04 Increased by +45.19% |
| Nov 9, 23 | -1.03 Increased by +28.97% | -1.05 Increased by +1.90% |
| Aug 10, 23 | -1.04 Increased by +23.53% | -1.23 Increased by +15.45% |
| May 12, 23 | -1.22 Increased by +19.21% | - |
| Mar 30, 23 | -1.14 Increased by +53.09% | -1.44 Increased by +20.83% |
| Nov 10, 22 | -1.45 Increased by +51.67% | -1.51 Increased by +3.97% |
| Fiscal ending date | RevenueChange YoY | IncomeChange YoY | ProfitChange YoY |
|---|---|---|---|
| Sep 30, 24 | 366.00 K Decreased by -79.12% | -2.59 M Increased by +31.45% | Decreased by -706.83% Decreased by -228.32% |
| Jun 30, 24 | 1.55 M Decreased by -15.84% | -5.81 M Decreased by -52.28% | Decreased by -374.42% Decreased by -80.93% |
| Mar 31, 24 | 5.88 M Increased by +292.60% | 825.00 K Increased by +119.14% | Increased by +14.02% Increased by +104.87% |
| Dec 31, 23 | 2.20 M Increased by +28.92% | -2.08 M Increased by +49.28% | Decreased by -94.60% Increased by +60.66% |
| Sep 30, 23 | 1.75 M Decreased by -6.36% | -3.77 M Increased by +23.01% | Decreased by -215.29% Increased by +17.78% |
| Jun 30, 23 | 1.84 M Increased by +38.54% | -3.82 M Increased by +16.95% | Decreased by -206.94% Increased by +40.06% |
| Mar 31, 23 | 1.50 M Increased by +29.22% | -4.31 M Increased by +13.31% | Decreased by -287.59% Increased by +32.92% |
| Dec 31, 22 | 1.71 M Increased by +274.56% | -4.11 M Decreased by -1.89% | Decreased by -240.46% Increased by +72.80% |